Changeflow GovPing Pharma & Drug Safety Small Molecule Inhibitors of Bacterial Efflux P...
Routine Rule Added Final

Small Molecule Inhibitors of Bacterial Efflux Pumps and Methods of Using Same

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

EPO granted patent EP3600331A1 to the Regents of the University of Colorado for small molecule inhibitors of bacterial efflux pumps and methods of using same. The invention covers pharmaceutical compositions containing these compounds and methods for treating bacterial infections. The patent is designated for all 31 contracting states including DE, FR, GB, IT, ES, NL, BE, CH, and others.

What changed

EPO published patent EP3600331A1 granting the Regents of the University of Colorado exclusive rights to small molecule inhibitors of bacterial efflux pumps and associated treatment methods. The patent covers compounds classified under A61K 31/65, A61K 31/426, A61K 31/506, and A61K 31/517, along with combination therapies and screening methods under C12Q 1/18.\n\nAffected parties including pharmaceutical manufacturers, biotech companies, and research institutions developing antibiotic therapeutics should conduct freedom-to-operate analyses before commercializing related products in designated EU states. The patent provides market exclusivity through the standard European patent term.

What to do next

  1. Monitor patent portfolio for freedom-to-operate
  2. Review designated states for market exclusivity

Archived snapshot

Apr 13, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

SMALL MOLECULE INHIBITORS OF BACTERIAL EFFLUX PUMPS AND METHODS OF USING SAME

Publication EP3600331A1 Kind: A1 Apr 01, 2026

Applicants

The Regents of the University of Colorado,
A Body Corporate

Inventors

REENS, Abigail, L., CROOKS, Amy, L., DETWEILER, Corrella, S.

IPC Classifications

A61K 31/65 20060101AFI20220201BHEP A61K 31/426 20060101ALI20220201BHEP A61K 31/506 20060101ALI20220201BHEP A61K 31/517 20060101ALI20220201BHEP A61P 31/04 20060101ALI20220201BHEP A61K 38/10 20060101ALI20220201BHEP A61K 45/06 20060101ALI20220201BHEP C12Q 1/18 20060101ALI20220201BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3600331A1

Who this affects

Applies to
Pharmaceutical companies Researchers and institutions Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Drug development Therapeutic compounds
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!